NICE, together with NHS England, remains committed to working with the company to try to reach a long-term deal that will give access to cerliponase alfa to all eligible people after that time.

This month we published a modular update to our health technology evaluations manual focusing on how we consider the effect of health technologies on health inequalities. The update is designed to ...

There is a simple discount patient access scheme for erdafitinib. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact ...

The 4 technology appraisal committees are standing advisory committees of NICE. This topic was considered by committee C. Committee members are asked to declare any interests in the technology being ...

This summary report is based on the NICE assumptions used in the resource impact template. Users can amend the 'Inputs and eligible population' and 'Unit costs' worksheets in the template to reflect ...

Erdafitinib (Balversa, Johnson & Johnson) is indicated for 'the treatment of adult patients with unresectable or metastatic urothelial carcinoma (UC), harbouring susceptible FGFR3 genetic alterations ...

Section 7 of the National Institute for Health and Care Excellence (Constitution and Functions) and the Health and Social Care Information Centre (Functions) Regulations 2013 requires integrated care ...

After considering the feedback from consultation, the appraisal committee has prepared final draft guidance (FDG) on erdafitinib for treating metastatic or unresectable FGFR-altered urothelial cancer ...

You should read both the consultation document and the accompanying evidence (see the committee papers) before making any comments. You must make your comments ...